Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
The addition of p‑Tau 205 and 212, on the ultra-sensitive Simoa platform, strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's Share
These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease. Developed on Quanterix's ultra-sensitive Simoa® platform, our p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers.
Quanterix's growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside.
'The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's,' said Masoud Toloue, PhD, CEO of Quanterix. 'Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we're advancing the future of precision diagnostics across neurology, oncology, and immunology.'
The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia.
To learn more about the new assays or Quanterix's expanded capabilities, visit www.quanterix.com or stop by the Quanterix booth at AAIC 2025.
About Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at www.quanterix.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
16 minutes ago
- New York Post
Take control of your finances with a QuickBooks Pro lifetime license
Discover startups, services, products and more from our partner StackCommerce. New York Post edits this content, and may be compensated and/or receive an affiliate commission if you buy through our links. TL;DR: Manage your finances the affordable way with help from an Intuit® QuickBooks® Desktop Pro Plus Lifetime License now available for $250 (reg. $699). Keeping your business finances in order shouldn't be a constant uphill battle. But with today's subscription-heavy software market and bloated cloud platforms, small business owners are left paying more to get less. If you're tired of handing over monthly fees just to use basic tools, Intuit® QuickBooks® Desktop Pro Plus 2024 offers a smarter, one-time solution that puts you back in control, and a lifetime license is on sale now for $249.99 (reg. $699). This version of QuickBooks gives you a lifetime license. No recurring charges, no locked features behind paywalls, and no online access requirements. It runs locally on your Windows machine, meaning your financial data stays with you, not floating in someone else's server, open to security risks or third-party access. For business owners who want privacy and control, that's a clear advantage. New York Post Composite The software is loaded with the tools you actually need. You can create invoices, track expenses, manage vendors and customers, run detailed reports, and monitor inventory, all without needing an internet connection or handing over your information to some distant corporate server. You also get job costing, asset tracking, and time tracking features that help you manage operations without relying on extra services. This license is authorized through an official Intuit® ProAdvisor reseller and installs on up to two devices for a single user. You'll also receive all software updates, but none of the usual support from Intuit®. That's part of the tradeoff for a deal that keeps Big Tech out of your books. For business owners fed up with subscription creep and cloud overreach, QuickBooks® Desktop Pro Plus 2024 brings accounting back where it belongs: under your control, and paid for once, not forever. Right now, it's only $249.99 to get an Intuit® QuickBooks® Desktop Pro Plus Lifetime License. StackSocial prices subject to change.
Business Insider
19 minutes ago
- Business Insider
Meta Platforms (META) was downgraded to a Hold Rating at Freedom Capital Markets
Meta Platforms received a Hold rating and an $800.00 price target from Freedom Capital Markets analyst Saken Ismailov today. The company's shares opened today at $776.45. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Ismailov is ranked #7654 out of 9859 analysts. In addition to Freedom Capital Markets, Meta Platforms also received a Hold from BMO Capital's Brian Pitz in a report issued on July 31. However, today, Loop Capital Markets reiterated a Buy rating on Meta Platforms (NASDAQ: META). Based on Meta Platforms' latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $47.52 billion and a net profit of $18.34 billion. In comparison, last year the company earned a revenue of $39.07 billion and had a net profit of $13.47 billion Based on the recent corporate insider activity of 287 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of META in relation to earlier this year. Most recently, in May 2025, SUSAN J LI, the CFO of META bought 13,859.00 shares for a total of $8,923,532.92.
Yahoo
38 minutes ago
- Yahoo
Amalgamated Financial (AMAL) Stock Trades Down, Here Is Why
What Happened? Shares of socially responsible bank Amalgamated Financial (NASDAQ:AMAL) fell 5.8% in the afternoon session after an analyst at Piper Sandler downgraded the stock to 'Underweight' from 'Neutral,' citing potential political and regulatory pressures. The investment firm also slashed its price target to $27 from $34. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Amalgamated Financial? Access our full analysis report here, it's free. What Is The Market Telling Us Amalgamated Financial's shares are not very volatile and have only had 6 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. Amalgamated Financial is down 17.2% since the beginning of the year, and at $27.47 per share, it is trading 28% below its 52-week high of $38.13 from November 2024. Investors who bought $1,000 worth of Amalgamated Financial's shares 5 years ago would now be looking at an investment worth $2,370. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
